Falling in Love with the MiniMed 630G System

Falling in Love with the MiniMed 630G System

In August, we launched the MiniMed 630G system in the U.S. Some of the first customers on the new system were employees, and among them is Naomi Ruperto, social community manager in Northridge, who has worked at Medtronic for more than seven years. This week, she shares her very positive experience with the new system. It truly makes me happy and incredibly proud to know that our employees are among the lives that we’re transforming with our therapies.

I think I’m in love.

And it’s not with my husband or my bulldog (although, I do love them!)

I think I’m in love with my new MiniMed 630G system.

Before I tell you why, let me back up a little bit and tell you my story. When I was 12 years old, my life forever changed when I was diagnosed with type 1 diabetes. I was the first in my family with diabetes, and the learning curve of my new life and managing my disease felt like a 90-degree angle for all of us.

After one year of injecting myself eight times a day, every day – my family and I looked into my first insulin pump. With the guidance of my endocrinologist, we chose a Medtronic pump because of the company’s reputation for excellent customer service. That was in 2002, and I’ve never looked back. Since then, I’ve always had the latest and greatest diabetes technology. I strongly believe in the value of an integrated system and have had great success with insulin pumps and continuous glucose monitors (CGM) over the years. I joined Medtronic as an intern in 2009, and have been part of the Chief Patient Office since July 2015.

On October 7, I was able to transition to the new MiniMed 630G system, and I literally could not be happier.

Here are four of my favorite things about the new system:

  1. The color screen is SO refreshing. Having a new view on my diabetes technology after all of these years is amazing. The first time I looked at my pump screen at night was an extremely special moment. The auto-adjust brightness is genius and the screen is also crisp and clear.
  2. The menu is very user-friendly. I was a little nervous to upgrade from the Paradigm platform after all of these years, but it was a very smooth adjustment because the system is so intuitive. It feels like it was created with consumers in mind, and fits in nicely with the other technology in my life, like my new iPhone 7.
  3. There are many options to personalize my settings in very meaningful ways, from pre-set temp basal rates, to adjustable CGM settings. This means less steps and less head-space to do daily tasks that can be frequent in my life.
  4. Another great thing about being on the new pump platform is that it will allow me to be first in line to upgrade to the MiniMed 670G system in the spring.

I thought that I would like it, but I love it.

It has greatly exceeded my expectations and I am so excited for this new phase in my diabetes management. From the bottom of my heart, thank you to each and every person who helped make this product a reality. From human factors and engineering, to regulatory and marketing, there are so many people who have put in years of hard work. Don’t ever lose sight of the difference that you make. And if you do, just remember that there are people like me every single day opening their new pump box and falling in love.

Thank you again and keep up the great work!

Editor’s Note: While Naomi is one of the first group of people to get started on a MiniMed 630G system, you may have also heard that Medtronic recently received FDA approval for the MiniMed 670G system, the world’s first hybrid closed loop system. We won’t have that product available until the spring, but that’s no reason to wait. Through our Priority Access program, customers can get started on MiniMed 630G system now and will be first in line for the MiniMed 670G system once available, and have the opportunity to get used to the new MiniMed pump platform. Restrictions may apply.

IMPORTANT SAFETY INFORMATION

The MiniMed 630G system with SmartGuard™ is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of diabetes mellitus in persons, sixteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 630G system includes SmartGuard, which can be programmed to temporarily suspend delivery of insulin for up to two hours when the sensor glucose value falls below a predefined threshold value.

The MiniMed 630G system is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the MiniMed 630G system.

The MiniMed 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the SmartGuard suspend on low alarm to take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.

Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms.

WARNING: Do not use the suspend on low feature to prevent or treat low glucose. The suspend on low feature is designed to suspend insulin delivery when you are unable to respond to the suspend on low alarm. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional. Using suspend on low to prevent or treat low glucose may result in prolonged hypoglycemia.

Please visit www.medtronicdiabetes.com/importantsafetyinformation for more details.

The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard HCL technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed 670G system consists of the following devices: MiniMed 670G insulin pump, the Guardian Link (3) transmitter, the Guardian Sensor (3), One-Press Serter, and the Contour NEXT Link 2.4 glucose meter. The system requires a prescription.

The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a home blood glucose monitor and not on values provided by the Guardian Sensor (3).

WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

WARNING: Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the 670G system has not been studied in pregnant women.

For complete details of the system and its components, including indications, contraindications, warnings and precautions associated with each, please consult the appropriate User Guide.

Print This Post Print This Post
Tags: , ,

Post A Comment

Your email address will not be published. Required fields are marked *